Abstract: The development of prognostic and diagnostic biomarkers, such as those from gene expression studies, requires independent validation in clinical specimens. Immunohistochemical analysis on tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tissue is often used to increase the statistical power, and it is used more often than in situ hybridization, which can be technically limiting. Herein, we introduce a method for performing quantitative gene expression analysis across a TMA using an adaptation of 2D-RT-qPCR, a recently developed technology for measuring transcript levels in a histologic section while maintaining 2-dimensional positional information of the tissue sample. As a demonstration of utility, a TMA with tumor and normal human prostate samples was used to validate expression profiles from previous array-based gene discovery studies of prostate cancer. The results show that 2D-RT-qPCR expands the utility of TMAs to include sensitive and accurate gene expression measurements.
G ene expression profiling is currently used for analyzing patient samples in the research setting; however, the field of molecular diagnostics is now moving toward utilization of expression patterns to predict clinical outcomes in patients. [1] [2] [3] Expression microarrays frequently serve as the discovery method and are used to measure a large number of genes in relatively few specimens. Subsequently, the candidate dysregulated genes must be validated by measuring their expression in a larger independent sample set. 4 At present, follow-up validation of profiling data is relatively low throughput. Therefore, it is common to perform immunohisto chemical analysis on a large cohort of patient samples of formalin-fixed and paraffin-embedded tissue (FFPE), including the tissue microarray (TMA) formats, to assess protein levels in a gene by gene manner. However, transcriptome-wide correlation between protein abundance and mRNA expression levels has been reported to be poor. 5 Moreover, there is unique and important biological information contained in the expression status of the transcripts themselves, independent of the protein products, and thus it would be useful to validate mRNAs in addition to their corresponding proteins.
Workflows for semiquantitative or fully quantitative mRNA expression validation applied to a tissue section include in situ hybridization (ISH), in situ RT-PCR, microdissection with subsequent RT-qPCR, and macrodissection with RT-qPCR. Each of these methods has significant limitations such as measuring only highly abundant transcripts and/or the labor intensiveness of the upfront isolation method. 6, 7 For example, ISH can semiquantitatively detect medium and high abundance mRNAs in a tissue section by direct hybridization of a labeled probe. ISH has technical challenges when detecting low copy number mRNAs from FFPE tissue, and this is a great limitation because the majority of the transcriptome is found in low-abundance target genes, 8 and thus in situ RT-PCR is required to detect and quantify mRNA targets in FFPE tissue sections. Although this method can sometimes provide sensitive and localized detection of low-abundance transcripts, in situ RT-PCR has proven difficult to employ for consistent and reliable measurements. 6, 7 Laser-based microdissection allows sensitive and reproducible mRNA quantification by isolating specific cells of interest from a histologic tissue section followed by quantitative RT-qPCR and produces accurate expression data. However, microdissection is both time and labor intensive. In contrast, macrodissection, which involves removing a region of a histology slide by scraping with a razor blade or other mechanical tool, is faster than microdissection; however, the recovered mRNA is derived from a mixture of cells, potentially confounding the results. [9] [10] [11] [12] In addition, for both microdissection and macrodissection, the RT-qPCR step itself is laborious to perform simultaneously on a large number of samples because of the extensive number of experimental steps involved. [13] [14] [15] These challenges are further compounded when using archival FFPE tissue samples because of the inherent poor RNA quality. [16] [17] [18] To address these limitations, our laboratories recently developed 2D-PCR 6 and 2D-RT-qPCR 7 technologies, which provide a means to mechanically separate a tissue section into individual subregions for qPCR and RT-qPCR measurements but without the need for laser microdissection or slide scraping. During the procedure, a multi-well array maintains the 2D layout of the tissue, and the tissue lysis and mRNA purification steps are performed in parallel to minimize the handling time per sample. We have shown successful DNA and cDNA (mRNA) amplification and measurements across frozen tissue sections. 6, 7 In the present report, we describe the adaptation of 2D-RT-qPCR to a TMA constructed of archival FFPE tissue specimens and an optimized workflow for its use in the Fluidigm Biomark qPCR assay (Fig. 1) . 2D-RT-qPCR was applied to a TMA containing human prostate normal and tumor specimens, allowing us to examine the differential expression of 22 mRNA targets across 42 FFPE prostate samples in a single experiment. Our results were then validated in silico by comparing data pooled from 14 independent microarray studies.
MATERIALS AND METHODS

Tissue Samples and 384-Well Format TMAs
Tissue samples were obtained from the Tissue Array Research Program at the National Cancer Institute (Bethesda, MD) to construct the prostate TMA. Tissue was also obtained for the supplementary studies from the National Cancer Institute, the Cooperative Human Tissue Network, and Pel-Freez Biologicals. Human tissue was obtained either with appropriate bioethics approvals or exemptions from the Office of Human Subjects Protection, NIH. A pathologist (J.R.C.) verified that the cores represented tumor or normal tissue and graded the tumors on the Gleason scale. Tissue microarrays were constructed by standard methods. A 384-well format grid (384-well hardskirted plates; Bio-Rad, Hercules, CA) was cut to fit into an aluminum macroembedding mold of 2 00 Â 3 00 (Super metal base molds, Leica, Wetzlar, Germany). The grid was covered in a thin layer of paraffin (Paraplast X-tra; St. Louis, MO). Individual TMA cores of 3.0 mm were extracted from archival tissue blocks and centrally embedded vertically into the holes in the grid. The mold was then filled with paraffin and chilled at 41C for 15 minutes.
Tissue Sectioning
TMA blocks were sectioned to 10 mm thickness using a standard microtome (RM2255; Leica, Wetzlar, Germany) onto adhesive film to obtain a uniform thickness for the transfer step (Fig. 1C) . The film (ARCare 7759; Adhesives Research, Glen Rock, PA), was placed adhesive-side against the TMA and pressed with a roller to create consistent contact. The TMA on the adhesive was deparaffinized in xylene for 60 seconds at room temperature, then dried in a chemical hood for 10 minutes.
Pretreatment for Recovering mRNA and Transfer to 384-Well Plates
After dewaxing, tissues were exposed to steam in an unpressurized vessel (Vegetable Steamer; Black & Decker, New Britain, CT) filled with double-distilled water for 30 minutes. Tissues were then allowed to air dry for 10 minutes. The adhesive-bound, steam-treated tissue was aligned over a clear 384-well flat-top PCR plate (KBioscence/LGC genomics, Middlesex, UK), where the burr from the flat top of the plate was removed with a blade. This style of plate aids sealing and allows the user to see what is in each well. The film containing tissue was applied such that only a single TMA core was placed in alignment over a single well, as shown in Figure 2 . The wells were preloaded with lysis buffer (see below) before the film was applied. The plate was then placed in a PTC-200 thermocycler (MJ Research/Applied Biosystems, Foster City, CA) in a compression rig 6 to apply 200 pounds of force and 601C to the adhesive for 3 minutes, sealing the film to the plate.
Lysis and Purification
Each well of the plate was preloaded with 14 mL of ChargeSwitch lysis buffer (ChargeSwitch RNA cell kit; Invitrogen/Life Technologies, Grand Island, NY) containing 0.2 mg/mL proteinase K and 5 mM dithiothreitol. After the plate was sealed, it was inverted, placed back into the compression rig under 200 pounds of force, and heated to 501C for 24 hours. After lysis, the plate was centrifuged, and the adhesive film containing the residual tissue core material was peeled off and discarded. A 7 mL solution containing 0.33 mL ChargeSwitch magnetic beads, 1% acetic acid, and 6.6 mL ChargeSwitch binding buffer was added to each well. Total RNA was thereby bound to the surfaces of the beads. The beads were immobilized to the side of each well using a magnet, and the wells were washed twice each with ChargeSwitch wash buffers 13 and 14, removing the magnet between steps. Wash 14 was then removed, with the magnet in place, and the total purified RNA on the beads was assayed either directly by one-step RT-qPCR (Supplemental Digital Content 1, http://links. lww.com/PDM/A54) or indirectly by preamplification followed by Fluidigm qPCR (see below).
Tandem mRNA Preamplification and Fluidigm Assay
After the purification procedure, a preamplification mixture was added to the beads, still in the same plate. The preamplification procedure is similar to the one used by Stanley and Szewczuk. 19 One-Step AgPath ID reversetranscriptase PCR mix was prepared according to the manufacturer's instructions except that twice as much enzyme mix was used, and TaqMan primer/probe sets (Supplemental Digital Content 1, http://links.lww.com/ PDM/A54) were diluted 450-fold (to 40 nM) for each primer set. To each well, 10 mL of this reaction mix was added. The plate was heated to 501C for 60 minutes, 951C for 15 minutes, and thermocycled for 14 cycles of 951C for 15 seconds and 601C for 4 minutes. The templates were diluted only 4-fold for use in the Fluidigm 48Â 48 Dynamic Array chip (Fluidigm, South San Francisco, CA). The Fluidigm assay was run in a Biomark HD system according to the manufacturer's protocol, with the exception that a custom PCR mastermix was made as described in the Supplemental Digital Content 1, http://links.lww.com/ PDM/A54. The experiments were performed by Dr Kelley Banfield at SAIC-Frederick. Additional information is FIGURE 1. Conceptual schematic representation of the 2D-RT-qPCR method. A, A TMA block is obtained. B, The block is sectioned to 10 mm thickness on an adhesive film and dewaxed with xylene; steam is also applied to improve mRNA integrity. C, The film with tissue is transferred onto a multi-well plate. D, Total RNA is purified and extracted in each well using solid-phase magnetic purification beads. E, In the same multi-well plate, mRNA is converted to cDNA and preamplified by tandem one-step RT-PCR. F, The preamplified targets are removed from the plate and quantified using the Fluidigm Biomark RT-qPCR detection system. 
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Gene Expression Analysis and Statistics
The heat map in Figure 3 was generated using the ArrayMining.org application, 20 selecting the option for hierarchical clustering (with ebayes supervised feature selection) to place genes and samples into nearest-neighbor groups. Nondetected values were replaced with the average Ct for the gene across all samples with values, and they represented only a small percent of the data.
RESULTS
Development of 2D-RT-qPCR on FFPE TMAs
Evolution of the 2D-RT-qPCR assay from application to frozen tissue to FFPE tissue required extensive validation. A series of TMAs were constructed with different core diameters, cut at different thicknesses to determine optimal tissue sampling required for reliable results. Cores of 3 mm diameter, with 10 mm thickness were found to be optimal. Assay sensitivity, linearity, and reproducibility were also determined on a panel of control FFPE TMA tissue and were found to be similar to those of a previous Fluidigm study using commercially purified human reference RNA, which found 7% variation for high copy number targets and 46% and higher variations for low copy number targets. 21 Lastly, we tested the 2D-RT-qPCR method and the RecoverAll kit was provided, which showed improvements in RNA detection efficiency and workflow. Results of these studies and additional controls are described in the Supplemental Digital Content 1, http://links.lww.com/PDM/A54.
Validation of Gene Expression Profiles
A TMA containing tumor and normal human prostate FFPE cores was constructed of archival tissue blocks from the Tissue Array Research Program. The tissue blocks were routine clinical specimens and not originally procured for research purposes. Each core contained a majority of either tumor or normal cells as determined by a pathologist (J.R.C.). The TMA was sectioned at a 10 mm thickness, with each 3-mm-diameter core providing tissue with a volume of approximately 70 nL. To meet the sample-size limitation of the Fluidigm 48.48 BioMark assay, 42 cores and 5 controls (commercially purified mRNA or water) were tested. The Fluidigm assay also provides inlets for up to 48 probe sets.
Probe sets for the Fluidigm assay included 8 genes from a previous prostate study as a test set for validation (FOLH, TACSTD, ALCAM, GSTP1, CD10, TIMP3, STAT5B, CD69) 22 and 9 commonly dysregulated in cancer (AMACR, SOD2, JAK1, ANG, MUC1, VEGF, H1F1A, AR, and VHL). Five housekeeping genes provide a reference baseline (HPRT1, B2M, GUSB, CYPA, and GAPDH). The result is the application of 2D-RTqPCR, to assay 22 transcripts across 18 normal and 24 tumor prostate cores in duplicate.
Of the 2068 data points collected, 220 were positive and negative controls as described in the Supplemental Digital Content 1, http://links.lww.com/PDM/A54. For the remaining 1848 data points, raw RT-qPCR data are presented in heat map format (Fig. 3) . The data was collected from a single 10-mm-thick section of a TMA constructed of 3.0 mm diameter cores. The data demonstrate 2 key features of the 2D-RT-qPCR technology. First, consistency is shown by the near-perfect alignment of technical replicates of probe assays to each other. Second, the expression analysis reliably separated the tumor and normal samples as indicated by the clustering of groups. In summary, these data highlight the validity and reproducibility of the 2D-RT-qPCR technology when applied to the molecular analysis of FFPE TMA cores.
To accurately compare gene expression values between samples, the "DC t " was calculated as the expression of a target mRNA minus the average expression of 4 housekeeping genes (B2M, GUS, GAPDH, and CYPA) to reduce error in normalization for samples prepared by formalin fixation. 23 DC t were subjected to a 2-tailed t test (the Welch assumption, unequal variances) between the tumor and normal sample groups (n = 24 and n = 18) for each transcript. On the basis of this metric, we found genes that showed significant differential expression between the 2 groups (Fig. 4) .
Several of the genes showed expression changes that were in agreement with previously published results. 22 Specifically, FOLH, TACSTD, and ALCAM were upregulated in prostate cancer, whereas GSTP1, CD10, and TIMP3 were downregulated (Fig. 4) . Furthermore, STAT5B and CD69, 2 genes identified in our previous study 22 as differentiators of high and moderate grade tumors, were also differentially expressed in this TMA study. However, the differential expression of CD69 was not in agreement with previous work 22 as it was expressed lower in tumor cells compared with normal cells, a result that could be due to pathologic differences, such as the amount of infiltrating lymphocytes in the sample set. Several tumor-associated genes from the literature were evaluated in the prostate TMA using the 2D-RT-qPCR method and showed similar results to the published data. Specifically, AMACR was overexpressed in tumors; SOD2, JAK1, ANG, MUC1, and VEGF were underexpressed. In this study, H1F1A was overexpressed in prostate tumors with a fold change of 1.22, which is a marginal yet significant change. As another internal control, we found that HPRT1, another common housekeeping gene, had no differential expression. 
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The present results were evaluated against in silico microarray data sets from the Oncomine database. 24 To allow a comparison between these data, the DC t in this study were converted to fold change using the formula sgnðDC t ÞÂ2 abs DC t ð Þ ; where sgn(x) is À 1 for DC t <0 and 1 otherwise, and abs() is the absolute value. The average fold change of differentially expressed genes (t<0.05) from the TMA study was compared with a 14-study microarray dataset, which represented results from 905 prostate samples in total. 24 The average fold changes for the in silico results and for the TMAs are shown in Figure 5 , and additional data are provided in the Supplemental Digital Content 1, http:// links.lww.com/PDM/A54. To quantify the comparison, the Pearson r 2 ; correlation coefficient was calculated by comparing the fold change between the overlap in data sets and was found to be 0.86. It should be noted that H1F1A was not identified as differentially expressed in the in silico data. 24 Interestingly, not one of the microarray data sets identified differential expression in all of the 14 genes that were validated in this study. Overall, the data indicate that the 2D-RT-qPCR technology generates results with strong concordance with previous findings and is capable of accurate and meaningful mRNA measurements from a single tissue section of TMA derived from archival blocks.
DISCUSSION
We have described a novel application of 2D-RTqPCR to a TMA section that allows parallel purification and amplification of mRNA from archival tissue blocks. The Fluidigm assay enabled gene expression measurement of up to 48 mRNAs (or 24 in duplicate) from the samples. Sensitive, specific, and reproducible detection was shown for all transcripts tested and over a wide range of expression levels using archival FFPE patient samples. The technology allowed validation of previously reported gene expression profiles in prostate cancer by utilizing FFPE samples from various sources, highlighting its ability to analyze tissue preserved by the most common preservation method used in archival clinical specimens. 25 The ability to use a small amount of tissue (2.8 to 70 nL volume depending on TMA core size) for expression analysis opens the possibilities for TMAs to be employed for a wide variety of validation and other studies.
Compared with a widely used commercial kit (RecoverAll; Life Technologies, Grand Island, NY, see Supplemental Digital Content 1, http://links.lww.com/ PDM/A54), whose procedure takes 2 work days to complete (12 h) and required a handling time of 6 hours for studying a TMA with 24 tissue core, the 2D-RTqPCR workflow required only 4 hours with an actual handling time of 1 hour. The time savings came from the lack of macrodissection or manual transfer of tissue lysates. On the basis of these results, 2D-RT-qPCR is approximately an order of magnitude faster than traditional workflows.
Design and application of the TMA requires special attention. For example, as the TMA is consumed by sectioning, sample heterogeneity may cause divergence from the cell types initially observed (ie, tumor vs. normal), and this may occur unequally as some tissue cores are altered or depleted sooner than others. It is therefore routine practice to stain and visually check a TMA section after every 125 to 250 mm of sectioning to ensure the histopathology has not changed significantly. 26 Secondly, RNA quality is dependent on the FFPE-derived tissue used in the construction of the TMA 16, 17 and depends on the method of tissue preparation, fixation, and age. 27 Although numerous fixatives and fixation protocols have been designed to preserve RNA quality, there is currently no standard protocol. 18 Thus, the cores in a typical TMA may originate from blocks that were prepared in different research centers, using multiple fixation protocols. Therefore, to analyze mRNA in TMAs with tissues originating from multiple institutions, it is useful to compensate for RNA degradation by using the smallest amplicon size feasible for PCR and to normalize target mRNA values to housekeeping genes in the same samples to correct for sample-to-sample variability in RNA quality. 17, 28 2D-RT-qPCR may be useful in clinical research and diagnostic tests as it can improve sample throughput and use small volumes of tissue. In principle, it is possible to study up to 96 genes in 96 patient core samples by application of a larger TMA and 96Â 96 Fluidigm qPCR assays, and the system is amenable to automation. 2D-RT-qPCR could also be tailored to clinical diagnostic cancer tests that assay fewer than 96 genes, such as MammaPrint 2, 29, 30 or Oncotype DX, 3 while potentially decreasing the current diagnostic time, from 5 days in the case of the Oncotype DX. 3 Furthermore, preamplified cDNA assayed using the Biomark Fluidigm platform has excellent concordance with conventional RT-qPCR. 21, 31 Diagnostic tests such as MammaPrint and Oncotype DX depend on the general feature that tumor specimens have more RNA than the surrounding normal tissue, 32 and RNA pooled from tumor and normal tissues should already be enriched for tumor RNA. In these particular cases, the contribution of RNA from normal tissue does not affect the diagnostic result, thus allowing the use of gross macrodissection of a few tissue sections to provide sufficient template for a gene expression assay. However, Van De Vjver 2 found that some specimens did not have a high enough proportion of tumor tissue to allow for macrodissection, and these specimens could not be included in the study. In fact, many recent studies suggest that isolating cells by microdissection before a molecular test leads to dramatically different genetic profiles [10] [11] [12] 33 that may in principle change a diagnosis or guide clinicians to different treatment decisions. The use of smaller TMA cores in 2D-RT-qPCR may also help enrich samples for specific cell types before analysis.
